Lazertinib and Tagrisso go head to head
A key test of J&J’s targeted agent approaches, but Astra has a trick up its sleeve that could render this readout irrelevant.
The world's twelfth VEGF drug will be sold by Takeda
The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.
First-quarter biotech risers work hard for the win
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.